Cybin Inc (HELP) Stock AnalysisHELPCybin Inc

Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005. It operates in the Healthcare sector.

Currently, Helus Pharma (HELP) is not a good buy due to its declining price and negative financial performance. The stock is trading at $10.55, down 10.59% over the last five days and 14.71% over the last 20 days. The RSI is at 39.353, indicating bearish momentum. Furthermore, the company has reported significant net losses, with a net income of -46,995,000 CAD in Q4 2026, which raises concerns about its financial health. The main risk is the declining stock price, which has dropped from a recent high of $15.15 to its current level, reflecting a loss of investor confidence despite positive analyst ratings. Therefore, it is advisable to sell or hold off on buying until there are signs of recovery in both price and financial performance.